RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 Cardiovascular Safety of Linagliptin in Patients with Type 2 Diabetes
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 11
SP 14
OP 15
DO 10.1177/155989771311011
UL http://mdc.sagepub.com/content/13/11/14.2.abstract
AB Linagliptin is an oral hypoglycemic compound used in the treatment of T2DM. The target of the drug is dipeptidyl peptidase 4, an enzyme that is important in various functions including the metabolism of glucose. This article discusses the cardiovascular (CV) safety of linagliptin in nearly 9500 patients with type 2 diabetes mellitus with a wide spectrum of CV risk and treatment history, based on an analysis of 19 randomized controlled trials.